Rep. Thomas H. Kean, Jr. Sells Off Shares of Stryker Corporation (NYSE:SYK)

Key Points

• Representative Thomas H. Kean, Jr. sold shares of Stryker Corporation (NYSE: SYK) valued between $1,001 and $15,000 on August 25th, in addition to previous sales on July 31st.
• Stryker's recent quarterly earnings exceeded expectations, reporting $3.13 earnings per share and $6.02 billion in revenue, marking an 11.1% year-over-year increase.
• The company also declared a quarterly dividend of $0.84 per share, reflecting an annualized yield of 0.9% and a payout ratio of 44.50%.

Representative Thomas H. Kean, Jr. (R-New Jersey) recently sold shares of Stryker Corporation NYSE: SYK. In a filing disclosed on September 18th, the Representative disclosed that they had sold between $1,001 and $15,000 in Stryker stock on August 25th. The trade occurred in the Representative's "STATE STREET BANK & TRUST CO." account.

Representative Thomas H. Kean, Jr. also recently made the following trade(s):

• Sold $1,001 - $15,000 in shares of Microsoft NASDAQ: MSFT on 8/25/2025.
• Purchased $1,001 - $15,000 in shares of Canadian Pacific Kansas City NYSE: CP on 8/22/2025.
• Sold $15,001 - $50,000 in shares of Stryker NYSE: SYK on 7/31/2025.
• Sold $15,001 - $50,000 in shares of Johnson & Johnson NYSE: JNJ on 7/31/2025.
• Purchased $15,001 - $50,000 in shares of Check Point Software Technologies NASDAQ: CHKP on 7/29/2025.
• Sold $1,001 - $15,000 in shares of Adobe NASDAQ: ADBE on 7/29/2025.
• Purchased $1,001 - $15,000 in shares of Abbott Laboratories NYSE: ABT on 7/21/2025.
• Purchased $1,001 - $15,000 in shares of Prologis NYSE: PLD on 6/30/2025.
• Sold $15,001 - $50,000 in shares of Stryker NYSE: SYK on 6/26/2025.
• Sold $1,001 - $15,000 in shares of WESCO International NYSE: WCC on 6/23/2025.

Stryker Stock Performance

Shares of Stryker stock opened at $376.61 on Friday. The company has a quick ratio of 1.06, a current ratio of 1.78 and a debt-to-equity ratio of 0.70. Stryker Corporation has a twelve month low of $329.16 and a twelve month high of $406.19. The stock has a market cap of $143.98 billion, a price-to-earnings ratio of 49.88, a P/E/G ratio of 2.72 and a beta of 0.93. The company's fifty day moving average is $387.52 and its 200 day moving average is $379.19.

Stryker (NYSE:SYK - Get Free Report) last issued its quarterly earnings data on Thursday, July 31st. The medical technology company reported $3.13 earnings per share for the quarter, topping the consensus estimate of $3.07 by $0.06. Stryker had a net margin of 12.25% and a return on equity of 23.94%. The company had revenue of $6.02 billion for the quarter, compared to analysts' expectations of $5.92 billion. During the same quarter in the previous year, the firm posted $2.81 earnings per share. Stryker's revenue for the quarter was up 11.1% on a year-over-year basis. Stryker has set its FY 2025 guidance at 13.400-13.600 EPS. Sell-side analysts forecast that Stryker Corporation will post 13.47 EPS for the current year.

Stryker Announces Dividend

The business also recently declared a quarterly dividend, which will be paid on Friday, October 31st. Stockholders of record on Tuesday, September 30th will be issued a dividend of $0.84 per share. The ex-dividend date is Tuesday, September 30th. This represents a $3.36 annualized dividend and a dividend yield of 0.9%. Stryker's dividend payout ratio is 44.50%.

Insider Buying and Selling

In other Stryker news, Director Ronda E. Stryker sold 200,000 shares of the stock in a transaction that occurred on Wednesday, August 6th. The shares were sold at an average price of $376.45, for a total transaction of $75,290,000.00. Following the completion of the sale, the director directly owned 3,222,108 shares of the company's stock, valued at $1,212,962,556.60. This trade represents a 5.84% decrease in their position. The sale was disclosed in a filing with the SEC, which is available through the SEC website. Also, insider Viju Menon sold 500 shares of the stock in a transaction that occurred on Monday, August 25th. The shares were sold at an average price of $390.61, for a total transaction of $195,305.00. Following the sale, the insider directly owned 12,511 shares of the company's stock, valued at approximately $4,886,921.71. This trade represents a 3.84% decrease in their ownership of the stock. The disclosure for this sale can be found here. Company insiders own 5.90% of the company's stock.

Wall Street Analyst Weigh In

SYK has been the topic of several research reports. Truist Financial set a $415.00 price objective on shares of Stryker and gave the company a "hold" rating in a report on Monday, August 4th. Redburn Partners set a $420.00 target price on shares of Stryker in a report on Thursday. Wells Fargo & Company upped their target price on shares of Stryker from $435.00 to $445.00 and gave the stock an "overweight" rating in a report on Friday, August 1st. Evercore ISI upped their target price on shares of Stryker from $390.00 to $415.00 and gave the stock an "outperform" rating in a report on Tuesday, July 8th. Finally, Needham & Company LLC upped their target price on shares of Stryker from $442.00 to $448.00 and gave the stock a "buy" rating in a report on Friday, August 1st. Fourteen equities research analysts have rated the stock with a Buy rating and five have assigned a Hold rating to the stock. Based on data from MarketBeat, the stock currently has a consensus rating of "Moderate Buy" and an average target price of $430.33.

Institutional Inflows and Outflows

Institutional investors and hedge funds have recently modified their holdings of the stock. Consolidated Portfolio Review Corp lifted its holdings in Stryker by 4.2% in the 2nd quarter. Consolidated Portfolio Review Corp now owns 648 shares of the medical technology company's stock worth $256,000 after purchasing an additional 26 shares in the last quarter. Princeton Global Asset Management LLC grew its holdings in Stryker by 16.9% during the 2nd quarter. Princeton Global Asset Management LLC now owns 180 shares of the medical technology company's stock valued at $71,000 after buying an additional 26 shares in the last quarter. Sunflower Bank N.A. grew its holdings in Stryker by 4.0% during the 2nd quarter. Sunflower Bank N.A. now owns 696 shares of the medical technology company's stock valued at $275,000 after buying an additional 27 shares in the last quarter. Pitti Group Wealth Management LLC grew its holdings in Stryker by 3.2% during the 2nd quarter. Pitti Group Wealth Management LLC now owns 861 shares of the medical technology company's stock valued at $341,000 after buying an additional 27 shares in the last quarter. Finally, Sachetta LLC grew its holdings in Stryker by 58.7% during the 2nd quarter. Sachetta LLC now owns 73 shares of the medical technology company's stock valued at $29,000 after buying an additional 27 shares in the last quarter. 77.09% of the stock is owned by institutional investors.

About Representative Kean

Thomas Kean Jr. (Republican Party) is a member of the U.S. House, representing New Jersey's 7th Congressional District. He assumed office on January 3, 2023. His current term ends on January 3, 2027. Kean (Republican Party) is running for re-election to the U.S. House to represent New Jersey's 7th Congressional District. He declared candidacy for the 2026 election. Thomas Kean Jr. lives in Westfield, New Jersey. Kean earned a master’s degree from the Tufts University Fletcher School of Law and Diplomacy. His career experience includes working with the Environmental Protection Agency during the George H.W. Bush administration and as an advisor to former U.S. Representative Bob Franks, a firefighter, and an emergency medical technician. Kean has served as the vice president of a fire department.

About Stryker

Stryker Corporation operates as a medical technology company. The company operates through two segments, MedSurg and Neurotechnology, and Orthopaedics and Spine. The Orthopaedics and Spine segment provides implants for use in total joint replacements, such as hip, knee and shoulder, and trauma and extremities surgeries.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.